Fig 4. Relationship between CgA level changes and clinical response.

(A) Of the twenty-eight patients that received IP chemotherapy as the first-line treatment, sixteen of twenty-three with non-progressive disease (PR and SD) showed decreased or stable CgA levels; three out of five with progressive disease (PD) exhibited increased CgA levels. (B) Of the eighteen patients who received somatostatin analogs as the first-line treatment, twelve of thirteen with non-progressive disease had decreased or stable CgA levels; two of the five patients having progressive disease showed increased CgA levels.